Posted in | News

KBR to Construct Medicago’s Vaccine Research Unit in North Carolina

KBR (NYSE: KBR) today announced that its Building Group has been awarded a contract by Alexandria Real Estate Equities for the construction of Medicago’s new 90,000-square-foot Vaccine Research and Production Facility/Greenhouse in Research Triangle Park, N.C. The contract is valued at approximately $19 million. Site work is underway.

Medicago’s plant-based commercial grade vaccines facility will include an automated greenhouse, extensive laboratory, production facility and office space with the project’s total investment expected to exceed $32 million. Scheduled for completion in July 2011, the project is being managed from the Building Group’s Raleigh office. The project has received substantial federal funding from the Defense Advanced Research Projects Agency (DARPA) through a $21 million research grant to improve the process of producing large quantities of H1N1 vaccine.

“The Building Group is well known for its strong history in the construction of advanced research and development facilities, with an emphasis on vaccine production facilities,” said Luther Cochrane, Senior Vice President, KBR and Chairman of the Building Group. “I am confident that our team’s specialized expertise will serve the Medicago project well and lead us to another successful project completion in Research Triangle Park.”

Source: http://www.kbr.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.